<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744640</url>
  </required_header>
  <id_info>
    <org_study_id>EK-Nr. 92/05</org_study_id>
    <secondary_id>2005DR2296</secondary_id>
    <nct_id>NCT00744640</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma</brief_title>
  <acronym>GEMOXEL</acronym>
  <official_title>Gemcitabine, Oxaliplatin and Capecitabine (GEMOXEL) for Patients With Advanced Pancreatic Adenocarcinoma (APC): A Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Cancer League</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine is the mainstay of palliative chemotherapy for patients with advanced pancreatic
      cancer (APC). Recent randomized trials have shown increased clinical benefit with the
      addition of oxaliplatin and prolonged median survival with the addition of capecitabine to
      gemcitabine. Gemcitabine, capecitabine and oxaliplatin are 3 newer, well tolerated anticancer
      drugs with mild and non-overlapping toxicity profiles. We therefore propose a dose-finding
      and safety study of the triple combination gemcitabine, capecitabine and oxaliplatin in
      patients with APC (Phase I part), followed by a phase II part to assess preliminary efficacy
      of this triple combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

        -  Phase I: to determine the maximum tolerated dose (MTD) of oxaliplatin in combination
           with gemcitabine and capecitabine (GEMOXEL) in patients with APC

        -  Phase II: to assess any anti-tumor activity of GEMOXEL in patients with APC

      Secondary Objectives:

        -  to assess toxicity and safety of the combination treatment GEMOXEL in patients with APC

      Primary Endpoints:

        -  Phase I: Dose-limiting toxicity

        -  Phase II: Objective tumor response

      Secondary Endpoints:

        -  Toxicity at MTD according to NCI CTC 3.0

        -  Progression-free survival and Overall Survival
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival and overall survival</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study with triple combination chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, oxaliplatin, capecitabine</intervention_name>
    <description>gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically or histologically confirmed adenocarcinoma of the exocrine pancreas

          -  Disease non-resectable and locally advanced or metastatic

          -  Measurable disease or evaluable disease i.e. tumor marker CA19-9 at baseline ≥ 1.5 x
             upper limit of normal (ULN)

          -  Age &gt;18 years

          -  Karnofsky performance status ≥ 60%

          -  Life expectancy of at least 3 months

          -  Written informed consent

          -  Willing and able to comply with the protocol for the duration of the study

        Exclusion Criteria:

          -  Prior chemotherapy for pancreatic cancer

          -  Prior adjuvant radio- or radiochemotherapy for pancreatic cancer within 12 months of
             inclusion

          -  Known CNS metastases at the time of enrollment

          -  Neutrophil count ≤ 1.5 x109/l, platelet count ≤100 x109/l, hemoglobin ≤ 10g/dl

          -  Serum creatinine &gt; 1.25 x ULN

          -  ASAT, ALAT and alkaline phosphatase &gt; 2.5 ULN or &gt; 5 ULN in the presence of liver
             metastasis, Bilirubin &gt; 1.5 ULN (after treatment of obstructive jaundice eg. stent)

          -  Pregnant or breast feeding women (women of childbearing potential must have a negative
             pregnancy test at baseline)

          -  Men and women of reproductive potential who are not using an effective method of
             contraception

          -  Clinically significant cardiac disease (NYHA III-IV) or myocardial infarction within
             the last 12 months

          -  Neurological disease with dys-/paraesthesias &gt; grade 1 according to NCI CTC

          -  Any serious concomitant disorder incompatible with the trial (in the judgement of the
             investigator)

          -  Psychiatric disability thought to be clinically significant in the opinion of the
             investigator precluding informed consent or interfering with compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viviane Hess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cantonal Hospital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <state>BL</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital Liestal</name>
      <address>
        <city>Liestal</city>
        <state>BL</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clara Hospital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital Lucerne</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncocenter Hirslanden</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>January 11, 2010</last_update_submitted>
  <last_update_submitted_qc>January 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Viviane Hess</name_title>
    <organization>University Hospital Basel</organization>
  </responsible_party>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>palliative chemotherapy</keyword>
  <keyword>first-line therapy</keyword>
  <keyword>capecitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>dose-finding study</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

